DRG Epidemiology’s coverage of prostate cancer comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of prostate cancer for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report. In addition to forecasting incident and prevalent patient populations, we forecast the number of drug-treatment opportunities in specific lines of therapy.
DRG Epidemiology’s prostate cancer forecast will answer the following questions:
How will changes in the levels of exposure to known risk or protective factors affect the number of people diagnosed with prostate cancer per year?
In developing countries, what impact will economic growth and development have on the number of people diagnosed with prostate cancer per year?
How will improvements in survival change the number of people living with a diagnosis of prostate cancer?
How will a decline in the risk of recurrence change the number of people diagnosed with prostate cancer per year?
Of all people with prostate cancer, how many in each of the major mature pharmaceutical markets have been formally diagnosed?
Of all people diagnosed with prostate cancer, how many in each of the major mature pharmaceutical markets are drug-treated?
All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods. In addition, we provide a graphical depiction of the patient flow between or within different disease states for the countries considered in this report. These patient flow diagrams are provided at the regional level, but may be requested for any specific country or forecast year.
DRG Epidemiology provides at least ten years of forecast data for the following prostate cancer patient populations:
Drug-treatable prevalent cases by metastasization status.
Diagnosed incident cases by TNM and risk category.
Diagnosed prevalent cases by drug-treatment potential.
First-line MCRPCDTP treatment subpopulation(s).
Newly diagnosed high/very high risk (hormone-sensitive) DTP subpopulation(s).
First-line MCRPC drug-treatable population.
Prostate cancer biochemically recurrent (hormone-sensitive) drug-treatment opportunities.
Prostate cancer biochemically recurrent incident cases.
Prostate cancer newly diagnosed high/very high risk (hormone-sensitive) drug-treatment opportunities.
Second-line MCRPCDTP subpopulation(s).
… and many more (details available on request).
Note: Coverage may vary by country and region.